Lupus Nephritis Clinical Trials 2023

What are the top hospitals conducting lupus nephritis research?

In the realm of lupus nephritis, several hospitals are driving forward with clinical trials that hold promise for patients suffering from this challenging condition. Among them is the Prolato Clinical Research Center (PCRC) in Houston, which currently has two active trials dedicated to lupus nephritis. Although PCRC's involvement may seem relatively recent, having recorded its first trial in 2019, their commitment to advancing knowledge and treatment options for this disease is commendable. Similarly, Reliant Medical Research in Miami is making strides with two ongoing lupus nephritis trials and holds a unique distinction as they have already secured consent to conduct a groundbreaking study starting 2023.

Not far behind is Novartis Investigative Site located in sunny San Diego where two active lupus nephritis trials are underway. Their initiation of research into lupus nephritis began more recently than others when they recorded their first trial in 2020; nevertheless, their contribution shows immense potential for advancements on the horizon. Meanwhile, at the University of Colorado in Denver, researchers are working diligently on one active clinical trial addressing lupus nephritis after recording their initial effort back in 2011.

Last but not least among these leading institutions is Northwell Health situated in Great Neck. While they have one ongoing trial focused on understanding and treating this complex condition today, it's worth noting that Northwell Health has a rich history of conducting four previous studies related to lupus nephritis since embarking on their journey towards advancement back in 2016.

These hospitals represent beacons of hope for those who battle against lupus nephritis daily. The dedication showcased by these esteemed institutions indicates a promising future where new treatments and breakthroughs bring us closer to improving the lives of individuals affected by this debilitating disease

Which are the best cities for lupus nephritis clinical trials?

When it comes to lupus nephritis clinical trials, several cities emerge as prominent hubs for research and development. Houston, Texas; New york, New York; Miami, Florida; Atlanta, Georgia; and El Paso, Texas all host a significant number of active trials exploring innovative treatment options. These trials investigate the effectiveness of various drugs such as zetomipzomib, Daxdilimab Arm 1, Nipocalimab, VIB4920, Anifrolumab among others in managing lupus nephritis. Individuals seeking cutting-edge therapies and opportunities to contribute to medical advancements can look to these cities as potential centers for participation in clinical trials aimed at improving outcomes for lupus nephritis patients.

Which are the top treatments for lupus nephritis being explored in clinical trials?

The exciting world of clinical trials is paving the way for advancements in lupus nephritis treatment. Among the top contenders are obinutuzumab and anifrolumab, both currently being explored in active trials. Obinutuzumab has shown promise with two ongoing trials and a total of three all-time lupus nephritis trials since its introduction in 2015. Similarly, anifrolumab is making its mark with one active trial and two all-time lupus nephritis trials, also first listed in 2015. These innovative treatments offer hope for improved outcomes and brighter futures for individuals battling this complex condition.

What are the most recent clinical trials for lupus nephritis?

Exciting advancements in the treatment of lupus nephritis have emerged through recent clinical trials. One notable trial investigated the efficacy and safety of voclosporin, a promising candidate for managing this condition. Another study explored zetomipzomib, combined with standard-of-care treatments, as a potential therapeutic approach. Additionally, an innovative phase 1 trial examined KYV-101 CAR-T cells with lymphodepletion conditioning to target lupus nephritis specifically. Lastly, Daxdilimab Arm 1 showcased its potential benefits in mitigating symptoms associated with this chronic autoimmune disease. With these groundbreaking trials unveiling new possibilities for individuals affected by lupus nephritis, there is renewed hope on the horizon.

What lupus nephritis clinical trials were recently completed?

In the realm of lupus nephritis clinical trials, there have been several recent completions that hold great promise for advancing treatment options. Notably, Janssen Research & Development, LLC concluded a trial in September 2020 focused on assessing the efficacy of standard-of-care treatments. Furthermore, in September 2018, Novartis Pharmaceuticals wrapped up their CFZ533 trial aimed at exploring potential therapeutic interventions. Another significant milestone was achieved by Kezar Life Sciences with the completion of their KZR-616 study in March 2018. These collective efforts signify a dedicated pursuit to improve outcomes for individuals with lupus nephritis and ignite optimism within the medical community and patient population alike